Jack Allen
Stock Analyst at Baird
(0.83)
# 3,713
Out of 4,749 analysts
42
Total ratings
32.35%
Success rate
-15.04%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jack Allen
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CARM Carisma Therapeutics | Downgrades: Neutral | $10 → $1 | $0.46 | +117.49% | 3 | Dec 12, 2024 | |
| INKT MiNK Therapeutics | Maintains: Outperform | $8 → $4 | $9.16 | -56.33% | 2 | Nov 15, 2024 | |
| VOR Vor Biopharma | Maintains: Outperform | $22 → $14 | $1.42 | +885.92% | 3 | Nov 8, 2024 | |
| ACLX Arcellx | Maintains: Outperform | $77 → $106 | $68.13 | +55.58% | 5 | Nov 6, 2024 | |
| NTLA Intellia Therapeutics | Maintains: Neutral | $24 → $18 | $10.32 | +74.42% | 2 | Oct 25, 2024 | |
| TIL Instil Bio | Reiterates: Outperform | $180 | $22.26 | +708.63% | 9 | Sep 16, 2024 | |
| BLUE bluebird bio | Maintains: Outperform | $140 → $120 | $7.75 | +1,448.39% | 3 | Aug 15, 2024 | |
| MREO Mereo BioPharma Group | Initiates: Outperform | $8 | $3.01 | +165.78% | 1 | Jun 13, 2024 | |
| CRSP CRISPR Therapeutics AG | Maintains: Neutral | $46 → $52 | $41.59 | +25.03% | 2 | May 9, 2024 | |
| IMCR Immunocore Holdings | Initiates: Outperform | $84 | $32.88 | +155.47% | 1 | Oct 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $6 → $8 | $1.50 | +433.33% | 4 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $12 | $1.80 | +566.67% | 2 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $5 | $0.60 | +732.36% | 1 | Nov 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $28 | $1.30 | +2,053.85% | 1 | Jun 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $1.61 | - | 2 | May 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $6 → $9 | $5.45 | +65.14% | 1 | Oct 7, 2021 |
Carisma Therapeutics
Dec 12, 2024
Downgrades: Neutral
Price Target: $10 → $1
Current: $0.46
Upside: +117.49%
MiNK Therapeutics
Nov 15, 2024
Maintains: Outperform
Price Target: $8 → $4
Current: $9.16
Upside: -56.33%
Vor Biopharma
Nov 8, 2024
Maintains: Outperform
Price Target: $22 → $14
Current: $1.42
Upside: +885.92%
Arcellx
Nov 6, 2024
Maintains: Outperform
Price Target: $77 → $106
Current: $68.13
Upside: +55.58%
Intellia Therapeutics
Oct 25, 2024
Maintains: Neutral
Price Target: $24 → $18
Current: $10.32
Upside: +74.42%
Instil Bio
Sep 16, 2024
Reiterates: Outperform
Price Target: $180
Current: $22.26
Upside: +708.63%
bluebird bio
Aug 15, 2024
Maintains: Outperform
Price Target: $140 → $120
Current: $7.75
Upside: +1,448.39%
Mereo BioPharma Group
Jun 13, 2024
Initiates: Outperform
Price Target: $8
Current: $3.01
Upside: +165.78%
CRISPR Therapeutics AG
May 9, 2024
Maintains: Neutral
Price Target: $46 → $52
Current: $41.59
Upside: +25.03%
Immunocore Holdings
Oct 31, 2023
Initiates: Outperform
Price Target: $84
Current: $32.88
Upside: +155.47%
Aug 15, 2023
Maintains: Outperform
Price Target: $6 → $8
Current: $1.50
Upside: +433.33%
Jan 6, 2023
Upgrades: Outperform
Price Target: $12
Current: $1.80
Upside: +566.67%
Nov 2, 2022
Initiates: Outperform
Price Target: $5
Current: $0.60
Upside: +732.36%
Jun 3, 2022
Initiates: Neutral
Price Target: $28
Current: $1.30
Upside: +2,053.85%
May 18, 2022
Upgrades: Outperform
Price Target: n/a
Current: $1.61
Upside: -
Oct 7, 2021
Upgrades: Outperform
Price Target: $6 → $9
Current: $5.45
Upside: +65.14%